Table 3.
|
ANS activity |
|||
---|---|---|---|---|
|
lnLF |
lnHF |
||
Independent variable | β | P | β | P |
Age |
−0.197 |
0.375 |
−0.015 |
0.938 |
Sex |
0.252 |
0.086 |
0.237 |
0.063 |
Body mass index |
−0.024 |
0.880 |
0.047 |
0.733 |
GAF |
−0.004 |
0.978 |
0.046 |
0.724 |
Duration of illness |
−0.017 |
0.924 |
−0.157 |
0.300 |
CPZeq*1 |
−0.369 |
0.048*2 |
−0.415 |
0.011*3 |
BPDeq*4 |
−0.089 |
0.584 |
−0.259 |
0.070 |
DZPeq*5 | −0.201 | 0.219 | −0.151 | 0.284 |
*1The daily dose of antipsychotic drug was converted to approximate chlorpromazine equivalent.
*2,3Significant difference (P < 0.05).
*4The daily dose of anticholinergic antiparkinsonian drug was converted to approximate biperiden equivalent.
*5The daily dose of anxiolytic drug was converted to approximate diazepam equivalent.